(Q35853032)

10 August 2017

1 reference

title

Drug interactions in oncology (English)

1 reference

10 August 2017

1

Jos H Beijnen

1 reference

10 August 2017

2

Jan H M Schellens

1 reference

10 August 2017

publication date

1 August 2004

1 reference

Lancet Oncology Commission

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

489-496

1 reference

Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Clinical-pharmacological strategies to assess drug interaction potential during drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Drug interactions in palliative care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Pharmacokinetic drug interactions with anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Antineoplastic agents. Drug interactions of clinical significance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Pharmacokinetic drug interactions of commonly used anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Clinically relevant drug-drug interactions in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Mitomycin antitumour agents: a review of their physico-chemical and analytical properties and stability

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Cardiac safety of liposomal anthracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Taxanes: an overview of the pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Azathioprine and allopurinol: the price of an avoidable drug interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Phase I and pharmacokinetic study of oral paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Severe vincristine toxicity in combination with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Interactions between antiepileptic and chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

An adverse interaction between warfarin and capecitabine: a case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Interaction between paclitaxel and warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Lithium pharmacokinetics during cisplatin-based chemotherapy: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

DNA-based drug interactions of cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Effects of St. John's wort on irinotecan metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Drug interaction between St John's wort and nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Expression of the Human CYP3A4 Gene in the Small Intestine of Transgenic Mice: In Vitro Metabolism and Pharmacokinetics of Midazolam

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

A transgenic mouse expressing human CYP4B1 in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901528-1

7 January 2021

10.1016/S1470-2045(04)01528-1

Identifiers

DOI

1 reference

release_qonm7o6bbvfhrl5xvep6fvknue

10 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qonm7o6bbvfhrl5xvep6fvknue

24 November 2022

mapped directly with Wikidata item

1 reference